DA-R-EPOCH regimen: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 3: Line 3:
{{CMG}}; {{AE}} {{AV}}
{{CMG}}; {{AE}} {{AV}}


{{SK}}DA-EPOCH-R; Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone Regimen; EPOCH-R regimen; EPOCH-R; EPOCH-R regimen; Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin-Rituximab Regimen
{{SK}}DA-EPOCH-R; Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone/Rituximab Regimen; EPOCH-R regimen; EPOCH-R; EPOCH-R regimen; Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin-Rituximab Regimen


==Overview==
==Overview==

Latest revision as of 18:36, 31 March 2015

WikiDoc Resources for DA-R-EPOCH regimen

Articles

Most recent articles on DA-R-EPOCH regimen

Most cited articles on DA-R-EPOCH regimen

Review articles on DA-R-EPOCH regimen

Articles on DA-R-EPOCH regimen in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on DA-R-EPOCH regimen

Images of DA-R-EPOCH regimen

Photos of DA-R-EPOCH regimen

Podcasts & MP3s on DA-R-EPOCH regimen

Videos on DA-R-EPOCH regimen

Evidence Based Medicine

Cochrane Collaboration on DA-R-EPOCH regimen

Bandolier on DA-R-EPOCH regimen

TRIP on DA-R-EPOCH regimen

Clinical Trials

Ongoing Trials on DA-R-EPOCH regimen at Clinical Trials.gov

Trial results on DA-R-EPOCH regimen

Clinical Trials on DA-R-EPOCH regimen at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on DA-R-EPOCH regimen

NICE Guidance on DA-R-EPOCH regimen

NHS PRODIGY Guidance

FDA on DA-R-EPOCH regimen

CDC on DA-R-EPOCH regimen

Books

Books on DA-R-EPOCH regimen

News

DA-R-EPOCH regimen in the news

Be alerted to news on DA-R-EPOCH regimen

News trends on DA-R-EPOCH regimen

Commentary

Blogs on DA-R-EPOCH regimen

Definitions

Definitions of DA-R-EPOCH regimen

Patient Resources / Community

Patient resources on DA-R-EPOCH regimen

Discussion groups on DA-R-EPOCH regimen

Patient Handouts on DA-R-EPOCH regimen

Directions to Hospitals Treating DA-R-EPOCH regimen

Risk calculators and risk factors for DA-R-EPOCH regimen

Healthcare Provider Resources

Symptoms of DA-R-EPOCH regimen

Causes & Risk Factors for DA-R-EPOCH regimen

Diagnostic studies for DA-R-EPOCH regimen

Treatment of DA-R-EPOCH regimen

Continuing Medical Education (CME)

CME Programs on DA-R-EPOCH regimen

International

DA-R-EPOCH regimen en Espanol

DA-R-EPOCH regimen en Francais

Business

DA-R-EPOCH regimen in the Marketplace

Patents on DA-R-EPOCH regimen

Experimental / Informatics

List of terms related to DA-R-EPOCH regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords:DA-EPOCH-R; Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone/Rituximab Regimen; EPOCH-R regimen; EPOCH-R; EPOCH-R regimen; Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin-Rituximab Regimen

Overview

DA-R-EPOCH regimen refers to a chemotherapy regimen consisting of Dose-adjusted etoposide, prednisone, vincristine (Oncovin) ,Cyclophosphamide and doxorubicin (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas[1] and HIV-associated B-cell non-Hodgkin lymphoma[2]

Regimen

DADose-adjusted

RRituximab

EEtoposide

PPrednisone

Ovincristine (Oncovin)

CCyclophosphamide

Hdoxorubicin (Hydroxydaunorubicin hycrochloride)

Indications

References

  1. "NCI Thesaurus".
  2. Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF; et al. (2010). "Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma". Blood. 115 (15): 3008–16. doi:10.1182/blood-2009-08-231613. PMC 2858478. PMID 20023215.
  3. Higashide Y, Hayashi T, Hirayama D, Wagatsuma K, Aoki Y, Maruyama Y; et al. (2015). "[A Case of Primary Mediastinal(Thymic)B-Cell Lymphoma Successfully Treated with the DA-EPOCH-RR egimen]". Gan To Kagaku Ryoho. 42 (1): 119–22. PMID 25596693.